Androgen Receptor CAG Repeats: How Genetics Affect Testosterone Sensitivity, TRT Response, and Androgen Resistance

madman

Super Moderator
Always on point you know where it's at!

Dr. Zitzmann gets deep here!

Key Take Home Point!

* The clinically responsible synthesis is therefore precise: genotype may modify interpretation, but it does not yet rewrite the diagnosis of hypogonadism. A continuous CAG 15–35 × TT/FT response surface is the appropriate clinical tool. Its future value will depend on standardized measurement, repeated within-person data, tissue-specific outcomes, and proof that using the genotype improves decisions and outcomes.



================



* The biological effect of testosterone cannot be inferred from its circulating concentration alone. Androgen action is determined jointly by ligand availability, tissue steroid metabolism, androgen-receptor (AR) abundance and function, coregulatory context, and hypothalamic-pituitary-testicicular feedback.


* This critical translational review integrates the molecular biochemistry, historical discovery, population diversity, endocrine compensation, organ-specific phenotypes, and pharmacogenetics of the AR CAG repeat. The evidence supports a graded, tissue-dependent effect rather than a universal molecular switch. SBMA provides compelling proof that long polyglutamine tracts impair aspects of canonical AR action, but its neurodegeneration reflects additional ligand- dependent proteotoxic mechanisms and cannot be extrapolated linearly to ordinary alleles.


* AR CAG length should therefore be considered a quantitative modifier of androgen action. A continuous CAG-by-testosterone response surface spanning 15-35 repeats is proposed as a transparent framework.


*
Within the ordinary range, receptor effects are graded, modest, and tissue dependent.


* Signals around 23–25 repeats justify focused study, but no validated diagnostic cliff exists there or elsewhere in the common range.


* No adequately powered randomized trial has assigned testosterone dose or target concentration by CAG length, demonstrated superior patient-important outcomes, and externally validated safety. Current evidence therefore supports prespecified pharmacogenetic research, not CAG-based prescribing. If CAG is already known, it may provide context for an unexpectedly small or large response, particularly for prostate, erythropoiesis, hair, or sexual outcomes, but adherence, timing of blood sampling, formulation pharmacokinetics, SHBG/free testosterone, comorbidities, alternative symptom causes, and direct target-organ measurements should be examined first. Dose should not be increased solely because a tract is long, nor reduced solely because it is short.

*
The purpose of this review is therefore not to ask whether a single CAG cutoff is universally “normal” or “abnormal.” It is to determine what the repeat changes mechanistically, how endocrine compensation conceals or amplifies its effects, which phenotypes show reproducible modification, and whether the evidence is sufficient to change the interpretation of testosterone concentrations. Particular attention is given to the hypothesis that a man with longer CAG repeats may become functionally androgen-insufficient at a testosterone concentration conventionally considered adequate.




Beyond Testosterone: The AndrogenReceptor Exon-1 CAG Repeat fromMolecular Mechanism and KennedyDisease to Compensated AndrogenResistance and Precision Endocrinology (2026)

Michael Zitzmann




Abstract


The biological effect of testosterone cannot be inferred from its circulating concentration alone. Androgen action is determined jointly by ligand availability, tissue steroid metabolism, androgen-receptor (AR) abundance and function, coregulatory context, and hypothalamic-pituitary-testicicular feedback. A polymorphic CAG repeat in exon 1 of the X-linked AR gene encodes a variable polyglutamine tract in the intrinsically disordered N-terminal transactivation domain. Pathogenic expansion causes spinal and bulbar muscular atrophy (SBMA; Kennedy disease), in which partial androgen insensitivity coexists with an androgen-dependent toxic gain of function. Within the non- SBMA range, longer repeats usually—but not invariably—reduce AR-mediated transcription in experimental systems and may shift the relationship between serum testosterone and androgen- responsive phenotypes. This critical translational review integrates the molecular biochemistry, historical discovery, population diversity, endocrine compensation, organ-specific phenotypes, and pharmacogenetics of the AR CAG repeat. The evidence supports a graded, tissue-dependent effect rather than a universal molecular switch. SBMA provides compelling proof that long polyglutamine tracts impair aspects of canonical AR action, but its neurodegeneration reflects additional ligand- dependent proteotoxic mechanisms and cannot be extrapolated linearly to ordinary alleles. In population cohorts, longer common-range repeats are often accompanied by modestly higher total and free testosterone and sometimes higher estradiol, consistent with a shifted feedback set point. High luteinizing hormone is not obligatory. Phenotypic associations involving fertility, sexuality, body composition, metabolism, bone, mood, prostate, and cardiovascular traits are heterogeneous, whereas differential prostate and erythropoietic responses during testosterone therapy provide comparatively coherent pharmacogenetic signals. AR CAG length should therefore be considered a quantitative modifier of androgen action. A continuous CAG-by-testosterone response surface spanning 15-35 repeats is proposed as a transparent framework.



1795195428698.webp

1795195454565.webp

1795195466711.webp





1. Introduction: Androgen Concentration Is Not Androgen Action

Clinical andrology has necessarily organized diagnosis around circulating testosterone. Serum measurements are reproducible enough to support population reference intervals, trial eligibility criteria, and guideline thresholds, whereas receptor activity within muscle, bone, brain, prostate, adipose tissue, breast, skin, and the reproductive tract is not directly measurable in routine practice. This practical success can obscure a fundamental biological distinction: testosterone concentration describes ligand availability, not the magnitude of the response generated in an individual target tissue.
--

Androgen action is the product of several partially independent processes. Testosterone must be secreted, transported, delivered to tissue, and either act directly or undergo local conversion to dihydrotestosterone or estradiol. The resulting ligand-receptor complex must assume productive conformations, translocate, engage chromatin, recruit the appropriate cofactors, and regulate a cell- specific transcriptional program. Variation at any stage can alter phenotype without a commensurate change in serum testosterone. Conversely, feedback regulation can change serum testosterone in order to compensate for altered downstream sensitivity.cccdfdf
--
The polymorphic CAG tract in exon 1 of the AR gene is an unusually informative model of this distinction. It is common, directly translated into a polyglutamine sequence within a major transactivation domain, and situated on the X chromosome, making men hemizygous. At one extreme, expansion beyond the ordinary polymorphic range causes SBMA, which combines neuromuscular degeneration with clinical and biochemical evidence of androgen insensitivity. Across the common range, experimental and clinical studies have associated repeat length with differences in receptor function, endocrine feedback, reproductive traits, body composition, metabolic physiology, bone, mood, prostate biology, and response to testosterone.

--
A reduction in receptor activity may be compensated by higher testosterone; higher testosterone can increase estradiol; target tissues differ in steroid metabolism and coregulators; and age, adiposity, disease, treatment, and ancestry alter the background on which the genotype operates. Statistical adjustment for testosterone may remove part of the compensatory pathway, whereas failure to adjust may conflate androgen availability with receptor responsiveness.
--
The purpose of this review is therefore not to ask whether a single CAG cutoff is universally “normal” or “abnormal.” It is to determine what the repeat changes mechanistically, how endocrine compensation conceals or amplifies its effects, which phenotypes show reproducible modification, and whether the evidence is sufficient to change the interpretation of testosterone concentrations. Particular attention is given to the hypothesis that a man with longer CAG repeats may become functionally androgen-insufficient at a testosterone concentration conventionally considered adequate.






5.7. Conclusions From the Molecular and Historical Evidence

Four conclusions are sufficiently secure to anchor the remainder of the review. First, the exon-1 polyglutamine tract lies within a dynamic transcriptional hub, so length variation can change AR output without altering the hormone concentration. Second, the average direction of effect is reduced productive androgen signalling with increasing tract length, but no assay-independent decrement per repeat exists. Third, SBMA unites partial loss of physiological AR activity with an androgen- dependent toxic gain of function; the endocrine and neurological components share the mutant receptor but are not interchangeable. Fourth, the SBMA experience establishes biological plausibility for a CAG×testosterone interaction while imposing a strict boundary on extrapolation: the continuous clinical surface for CAG 15–35 must be estimated from human endocrine and phenotypic data, whereas alleles at and beyond the SBMA boundary require a separate toxicity dimension.




8.12. Testosterone-Treatment Response and Safety Pharmacogenetics


No adequately powered randomized trial has assigned testosterone dose or target concentration by CAG length, demonstrated superior patient-important outcomes, and externally validated safety. Current evidence therefore supports prespecified pharmacogenetic research, not CAG-based prescribing. If CAG is already known, it may provide context for an unexpectedly small or large response, particularly for prostate, erythropoiesis, hair, or sexual outcomes, but adherence, timing of blood sampling, formulation pharmacokinetics, SHBG/free testosterone, comorbidities, alternative symptom causes, and direct target-organ measurements should be examined first. Dose should not be increased solely because a tract is long, nor reduced solely because it is short.




1795196285098.webp





9.3. A Cautious Clinical Interpretation Sequence

When AR-CAG information is already available, interpretation should proceed in a fixed order (Figure 10).


1. Confirm the clinical phenotype. Separate specific androgen-dependent endpoints—sexual maturation, testicular function, anemia, low-trauma fracture, objectively reduced muscle function, or a treatment response—from nonspecific fatigue, depressed mood, obesity, sleep disturbance, or reduced vitality.

2. Establish hormone status correctly. Obtain at least two appropriately timed TT measurements in a stable state; assess SHBG and FT when TT is borderline or SHBG is altered; and measure LH, FSH, prolactin and other tests required to classify the axis. Repeat sampling is more informative than a precisely genotyped receptor paired with one noisy testosterone result.

3. Identify dominant acquired causes. Obesity, diabetes, sleep apnea, acute or chronic illness, opioids, glucocorticoids, hyperprolactinemia, undernutrition, excessive exercise, and testicular or pituitary disease can overwhelm the modest contribution of CAG length.

4. Verify the genetic result and counting convention. The laboratory should report the pure CAG count, whether the adjacent CAA glutamine codon is included, assay precision, and the reference transcript. A one-repeat technical discrepancy matters when authors use narrow categories.

5. Place the allele in the appropriate regime. Common-range variation should not be conflated with an AR coding mutation causing androgen-insensitivity syndrome. Alleles at the SBMA boundary require neurological and genetic interpretation; a common-range endocrine response model is inappropriate for pathogenic expansion.

6. Interpret CAG as an effect modifier. A result in the 23–25 region can raise the prior plausibility of modestly attenuated androgen action in a concordant clinical context, but it is not a positive diagnostic test. Values farther into either tail increase mechanistic interest while also increasing statistical uncertainty because they are less common.

7. Base treatment on established indications and outcomes. If testosterone therapy is otherwise indicated, CAG may motivate closer observation of organ-specific benefit and adverse response; it does not define a dose. Therapy should be titrated using symptoms, measured exposure, formulation pharmacokinetics, hematocrit, prostate monitoring where appropriate, fertility goals, and guideline-based safety procedures.


This sequence prevents two opposite errors: dismissing a genuine pharmacodynamic modifier because its average effect is small, and attributing a complex phenotype to one repeat while neglecting treatable causes.





10.7. Limitations of the Present Evidence Synthesis

This review is intentionally broad and PubMed-restricted. It captures the indexed biomedical literature and preserves verifiability, but it may omit non-indexed theses, conference abstracts, and regional journals. Its critical narrative design is appropriate for heterogeneous mechanisms and outcomes, yet it is not a single-outcome systematic review or meta-analysis. The high-sensitivity search yields overlap heavily across concept blocks; record counts therefore describe retrieval, not independent studies. Selection was guided by historical priority, direct relevance, study quality, and the need to represent positive and negative evidence.
--
Most importantly, the proposed response surface is a framework, not yet a fitted clinical instrument. Its conceptual rendering in this review visualizes hypotheses and evidence density; it does not assign treatment targets.




11. Conclusion

AR exon-1 CAG length helps explain why serum testosterone and androgen phenotype are related but not interchangeable. Kennedy disease established that a sufficiently expanded polyglutamine tract can produce partial loss of normal androgen action, while modern work shows that the same expansion also causes an androgen-dependent toxic gain of function. Within the ordinary range, receptor effects are graded, modest, and tissue dependent. Endocrine feedback often compensates with higher testosterone and sometimes higher estradiol; ageing, obesity, illness, or testicular failure may expose a mismatch between ligand availability and receptor sensitivity. Signals around 23–25 repeats justify focused study, but no validated diagnostic cliff exists there or elsewhere in the common range.
--
The clinically responsible synthesis is therefore precise: genotype may modify interpretation, but it does not yet rewrite the diagnosis of hypogonadism. A continuous CAG 15–35 × TT/FT response surface is the appropriate clinical tool. Its future value will depend on standardized measurement, repeated within-person data, tissue-specific outcomes, and proof that using the genotype improves decisions and outcomes.
 

Attachments

ExcelMale Newsletter Signup

Free ExcelMale Downloads: men's health guides, eBooks and resources

Sponsors

Online statistics

Members online
3
Guests online
862
Total visitors
865

ExcelMale Newsletter Signup

Back
Top